Page last updated: 2024-10-31

nafamostat and Hepatic Encephalopathy

nafamostat has been researched along with Hepatic Encephalopathy in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ogawa, M1
Mori, Y1
Ueda, S1
Mori, T1
Makino, Y1
Hori, J1
Ohto, M1
Wakashin, M1

Other Studies

1 other study available for nafamostat and Hepatic Encephalopathy

ArticleYear
Protective effects of FUT-175 on acute massive hepatic necrosis induced in mice following endotoxin injection and immunization with liver proteins.
    Journal of hepatology, 1993, Volume: 19, Issue:3

    Topics: Acute Disease; Animals; Autoimmune Diseases; Benzamidines; Chemical and Drug Induced Liver Injury; E

1993